Design Therapeutics price target raised to $5 from $4 at RBC Capital

RBC Capital raised the firm’s price target on Design Therapeutics (DSGN) to $5 from $4 and keeps a Sector Perform rating on the shares. The company has now entered the clinic with both of its key programs and remains on track for data updates in the first half on Fuchs, and potentially mid-year on successful SAD – single-ascending dose – to MAD – multiple ascending dose – progression for Friedreich’s ataxia, the analyst tells investors in a research note.